Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 3/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.58 |
| ▸ | FGFR4 | P22455 | 9/20 | 0.48 |
| ▸ | RIPK2 | O43353 | 6/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 6/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | CCND2 | P30279 | 1/20 | 0.46 |
| ▸ | CCND3 | P30281 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.45 |
| ▸ | WEE1 | P30291 | 2/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3977362 | 0.92 | LCK (0.55) | LCKMAPK14FGFR4RIPK2NOD2 | |
| SCHEMBL3970429 | 0.90 | LCK (0.65) | LCKMAPK14FGFR4RIPK2NOD2 | |
| SCHEMBL3971251 | 0.88 | LCK (0.60) | LCKMAPK14FGFR4RIPK2NOD2 | |
| SCHEMBL3968638 | 0.86 | FGFR4 (0.53) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL3972049 | 0.86 | LCK (0.53) | LCKMAPK14FGFR4RIPK2NOD2 | |
| SCHEMBL3977883 | 0.85 | LCK (0.61) | LCKMAPK14FGFR4RIPK2NOD2 | |
| SCHEMBL3967544 | 0.84 | FGFR4 (0.56) | LCKMAPK14FGFR4FGFR1FGFR2 | |
| SCHEMBL6622909 | 0.83 | LCK (0.84) | LCKMAPK14FGFR4RIPK2NOD2 | |
| SCHEMBL3972198 | 0.80 | LCK (0.46) | LCKMAPK14FGFR4RIPK2NOD2 | |
| SCHEMBL3976088 | 0.79 | FGFR4 (0.53) | FGFR4CDK4CCND1FGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | claimed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | claimed |
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | DOBRUSIN ELLEN MYRA (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | CCNI, CCNH, CCNA1 | LCK 117/4885MAPK14 447/4885FGFR4 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.